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Abstract To study prevalence, specific patterns and
response to treatment of tremor in dementia with Lewy
bodies (DLB), in comparison with other tremulous disor-
ders prevalence, qualitative and quantitative features of
tremor were studied in an incident cohort of 67 dopami-
nergic treatment naive DLB, 111 Parkinson’s Disease (PD)
and 34 Essential Tremor (ET) patients. Tremulous DLB
patients (tDLB) were compared with tremulous PD (tPD)
and ET patients and followed for 2 years. Double blind
placebo-controlled acute drug challenge with L-Dopa and
alcohol was performed in all ET, 24 tDLB and 27 tPD.
Effects of dopaminergic chronic treatment in all tDLB and
tPD patients and primidone in 8 tDLB were also assessed.
Tremor occurred in 44.76 % of DLB patients. The tDLB
patients presented a complex pattern of mixed tremors,
characterized by rest and postural/action tremor, including
walking tremor and standing overflow in 50 % tDLB.
Standing tremor with overflow was characteristic of tDLB
(p \ 0.001). Head tremor was more frequent in tDLB than
tPD and ET (p = 0.001). The tDLB tremors were reduced
by acute and chronic dopaminergic treatments (p \ 0.01)
but not by alcohol or primidone. Tremor occurs commonly
in DLB patients with a complex mixed tremor patternElectronic supplementary material The online version of this
article (doi:10.1007/s00415-013-6853-y) contains supplementary
material, which is available to authorized users.
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which shows a significant response to acute and chronic
dopaminergic treatments. Recognizing that there is a clin-
ical category of tremulous DLB may help the differential
diagnosis of tremors.
Keywords Dementia with Lewy bodies  Parkinson’s
disease  Tremor  EMG
Introduction
The last consensus on diagnostic criteria for dementia with
Lewy Bodies (DLB), states that ‘‘tremor is less frequent
than in Parkinson’s disease (PD)’’ [1] but does not detail
the types and relative prevalence of tremor, despite earlier
studies reporting a prevalence of 40 % for rest and 30 %
for action (kinetic-postural) tremor [2, 3].
Generally rest tremor is considered specific for PD,
while postural and action (or intentional) tremor are
attributed to essential tremor (ET), although exceptions to
this rule are clearly reported [4–6]. The prevalence of these
tremors have not been investigated in DLB after the early
reports, nor was described the prevalence of other types of
tremor which are considered infrequent but specific to PD,
as head and face tremors [7, 8], re–emergent [6, 9], pseudo-
orthostatic or standing tremor [5, 10–13]. In addition, while
there are some small studies reporting an improvement of
general motor features in DLB with acute L-Dopa chal-
lenge [14], the specific response of tremors to treatments
has been investigated in only one early study [15].
The clarification of the different tremor types and
response to treatment in DLB could improve clinical rec-
ognition of DLB, but mostly, understanding tremor in
DLB, would provide clarity to recent controversial debates
[16–24] on the long term outcome of patients putatively
affected by ET. Several reports showed that some ET
patients, during follow-up may present with additional PD
features, dopamine transporter capitation abnormalities, or
cognitive abnormalities, and may present with Lewy bodies
at the autopsy [16–21]. These observations were, more or
less dismissively, challenged in three different editorials
[22–24]. Yet, these discussions did not consider at all that
the action (kinetic, postural) tremors, of DLB may be
erroneously attributed to ET.
Therefore, our study aims to show characteristics and
treatment sensitivity of tremor in DLB in comparison with
tremor in PD and ET, in order to be of help to neurologists
attempting categorization of patients.
An incident cohort of DLB patients was evaluated and
followed for two years and compared with two cohorts of
incident PD and ET patients. Detailed and extensive evalu-
ation of any tremors present was carried out and response to
acute and chronic treatments was also investigated.
Methods
All new referrals to our movement disorders and memory
clinics in the years 2005–2009, (202 patients) diagnosed
with DLB, PD, or ET, according to the accepted clinical
criteria [1, 4, 25] were enrolled in the study. Exclusion
criteria were any prior exposure to neuroleptic drugs, the
presence of dystonia and the presence of classic orthostatic
tremor. The PD patients with dementia (PDD) were
excluded because of the confounding effects of treatments.
All patients tested negative for the G20195 mutations in
the LRRK2 gene [26] as a high prevalence of mixed tremor
has been described in this condition [27]. All patients were
followed for a minimum of two years to confirm/challenge
diagnosis.
The study was approved by our local ethical committee
and was carried out according to the declaration of Helsinki
and subsequent revisions [28]. Patients (or caregivers)
signed a written informed consent and authorization was
obtained for disclosure (consent-to-disclose) of any rec-
ognizable persons in videos. All patients received a full
neurological, neuropsychological, neuroimaging and neu-
ropsychiatric evaluation, as reported in Online Resource 1,
and as described in previous studies on the same cohort
[29–32]. Observation and recording of tremors were per-
formed only in dopaminergic drugs naive patients (all DLB
and 52 PD patients) or after withdrawal of L-Dopa (48 h) or
dopamine agonist (72 h) treatments (13 PD patients).
Tremor was rated using the Tremor Research Group Rat-
ing Scale (TRGRS) [6] quantified clinically according to the
TRGRS items. Face and jaw tremor were clustered in a single
item, tongue tremor was omitted as this was not observed, and
items 10 and 11 (hand writing and holding pencil) were
omitted as these items were not collected in all patients. Two
supplementary categories, absent in the TRGRS rating scale
were also applied: re-emergent tremor of the arm indicating
‘‘delayed re-emergence of rest tremor when the arm was
postured’’ [9] and standing overflow indicating overflow of
rest or postural tremor, when standing, to body districts not
primarily affected by the tremor. Standing tremor was defined
according to the TRGRS scale, and indicated the pseudo-
orthostatic tremor with the low frequency of parkinsonian
tremor or ET, described in PD or genetic PD [10–13].
Tremors frequencies and amplitudes were also quantified by
Electromyography (EMG) as described in our previous
papers [11, 12, 33] and in Online Resource 1.
Acute drug challenge was performed in 34 ET, 24 DLB
and 27 PD patients. Acute treatments were evaluated in the
three groups with blinded procedures. Alcohol test and
acute L-Dopa challenges were performed according to the
described protocols [15, 34–36]. An alcohol test was per-
formed in all ET, PD and DLB patients with tremor, in
blinded protocols. A target of 0.8 % (0.8 g/L) alcohol was
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reached by administering in 5 min, 8 fluid oz of orange
juice with artificial nonalcohol Rum flavour (placebo) or
orange juice with 40 % alcohol Rum. The needed amount
of alcohol was calculated for each patient according to
published body water formulas. The TRGRS rating was
performed by examiners unaware of the administered
substance 30–45 min after the administration according to
published observations on maximal tremor responses to
ethanol administration [34].
Double blind cross-over acute L-Dopa challenges (single
oral adminiostration L-Dopa/carbidopa 250/25 mg) [36]
were performed in patients never exposed to L-Dopa with
the TRGRS rated by examiners 90–110 min after drug or
placebo intake.
Primidone effect (250–500 mg/day) was evaluated in
eight DLB patients, who were taking this drug for presumed
ET prior to referral to our clinics. In these patients TRGRS
ratings and tremor assessments were performed during pri-
midone treatment and two weeks after withdrawal.
During the follow-up period all DLB and PD patients
received oral L-Dopa treatment and other treatments
according to their needs. Tremor ratings were repeated every
two to four months; the chronic treatment effect evaluation
was performed six months after the initial assessment.
Statistics
Demographic, clinical and neuropsychological/neu-
ropsychiatric differences between groups and time of
evaluation were estimated using either analysis of variance
for continuous variables (One-way ANOVA; ANOVA for
repeated measure) or non-parametric procedures as
appropriate (Wilcoxon test). Between-groups differences in
the prevalence of the specific types of tremor were inves-
tigated using the chi-square test. Stepwise logistic regres-
sion and ROC analyses were used to assess the best group
predictor among the types of tremor. Post hoc clustering of
TRGRS scores was applied to treatment effect evaluations
in order to simplify graphic rendering of data.
Correlations between tremor scores and neuropsycho-
logical tests were not applied because the range of scores
for cognitive variables clustered specifically in the DLB
population. All analyses were conducted using statistical
package SSPS 16.
Results
Patients characterization
Among the 202 new referrals to our movement disorders
and memory clinics during the years 2005–2009, 111 were
initially diagnosed with PD, 61 with DLB and 40 with ET.
Within two years from the ET diagnosis, six patients
were re-classified as DLB due to the appearance of cog-
nitive decline with all core and supportive consensus ele-
ments [1], including REM sleep behaviour disorder (RBD),
hallucinations, EEG abnormalities, and cognitive fluctua-
tions. In these patients DLB categorization, instead of PD
with Dementia (PDD), was considered acceptable despite
the fact that tremor had appeared before or was concomi-
tant with cognitive decline, as the tremor observed at first
referral was purely intentional-kinetic and all six had been
addressed to referral as ET patients and two of them were
temporarily treated with primidone until our re-evaluation.
Six more patients were treated with primidone according to
putative ET diagnosis, but in these patients the diagnosis of
DLB was completed at first referral. Figure 1 shows the
study design-flow chart with categorization of patients.
Thus, a total of 67 patients were ultimately classified as
DLB and 34 as ET. Two PD patients, presenting with rest/
action and standing tremor, developed cognitive impair-
ment and neuropsychiatric symptoms and were reclassified
PDD [37] .
Demographic and clinical characteristics, with statistical
comparisons, of the three groups at baseline and follow up
are reported in Table 1. Age, results of cognitive tests and
the degree of cognitive decline at follow-up significantly
separated DLB patients from PD and ET. Onset of tremor,
onset of dementia and other clinical characteristics in the
eight patients treated with primidone prior to our re-clas-
sification into DLB was not statistically different in com-
parison to the other 22 tremulous DLB patients.
Prevalence of tremor
Tremor was observed in 30 DLB and 65 PD patients.
Overall, patients with tremor represented 44.77 % of the
DLB cohort (tDLB) and 58.56 % of the PD cohort (tPD).
Their characteristics at baseline and follow up are reported
in Table 2; there were minor differences between tDLB
and nontremulous DLB (age, disease duration and cogni-
tive function) but no differences between PD subgroups.
Phenomenology of tremors and relative prevalence
Table 3 shows severity and prevalence of tremor types in
the tDLB, tPD and ET groups based on the TRGRS scores.
The table shows that the full range of tremors, including
head and face tremors, was observed with different severity
and prevalence in the three groups of patients. Limb tremor
was more frequently bilateral in tDLB as compared to tPD
(73.3 % vs. 9.2 %, v2 = 40.6; p \ 0.001).
The ET tremor was bilateral as a result of selection
criteria [3,4]. The overlap of tremor types in the same
patients is graphically represented in Fig. 2, and Table 3
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shows that tDLB was characterized by several tremor types
including overlapping mixtures of head and face, rest,
postural, action (spiral drawing, pouring water) and walk-
ing (re-emergence of rest arm tremor when walking) tre-
mor. Almost all of the tDLB patients (97 %) expressed
more than one type of tremor.
Head and face tremor was more frequent in tDLB
compared to tPD (26.7 % vs. 3.1 % for head tremor
v2 = 12.1 p = 0.001; 40.3 % vs. 24.6 % for face tremor;
v2 = 3.4 p = 0.06). Voice tremor (bleating voice) was
observed only in 6 ET (17.6 %).
For tDLB, 44.9% presented with a complex pattern of
mixed tremor which consisted of rest, postural, and action
tremor and these were associated with walking and/or
standing tremor.
This mixed tremor appeared as hand pill-rolling tremor
at rest and when walking but action tremor was also evi-
dent when patients attempted to perform the spiral draw-
ing/pouring water TRGRS tasks or when the patient was
asked to write.
Standing posture elicited tremor of lower limbs (stand-
ing or pseudo-orthostatic tremor) in 53.3 % of tDLB
patients, and 4.6 % of PD patients (v2 = 24.4; p \ 0.001).
Leg tremor disappeared when walking whilst tremor of
arms appeared. Only one ET patient showed standing tre-
mor, but no walking tremor. Two PD patients with standing
tremor presented during follow-up with features of PDD.
A specific characteristics of the mixed tremor observed
in DLB patients was an overflow phenomenon elicited by
the standing posture with outstretched arms, characterised
by the diffusion of tremor to all the different body parts;
this overflow was observed in 46.6 % of DLB patients but
only in 3.1 % of PD patients (v2 = 27.8; p \ 0.001). This
overflow tremor appeared as hand pill-rolling tremor at rest
and when walking but kinetic tremor was also evident
when patients were attempting the spiral drawing/pouring
water TRGRS tasks or when the patient was asked to write.
When these patients were evaluated in a standing position
with outstretched arms, tremor appeared in the hands with
a latency of 3–15 s and a progressive overflow to lower
limbs was observed in 5–30 s. The latency of rest tremor
reappearance when acquiring the outstretched arm position
was 10.2 ± 4.63 s which contrasted with the almost
immediate occurrence of postural tremor in ET, at
1.68 ± 2.27 s (Wilcoxon tests, Z = -2.93, p = 0.003).
Figure 3 shows the EMG pattern of progressive over-
flow. The TRGRS scores or tremor frequencies were not
statistically different when rest, postural or action tremors
Fig. 1 Flow chart of the study:
referral to clinics, selection of
patients according to
instrumental evaluation
proposed by Consortium
Consensus criteria, and drug
effect assessments. The
comparative analysis was
performed only in patients
whose diagnosis was not
challenged during the follow-
up. The asterisk indicates that
the two patients who developed
PDD during follow-up were
considered in the 65 patients of
the PD group
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were compared with tremor appearing in standing position
(F = 0.57; p = 0.68 for TRGRS score; F = 0.46;
p = 0.76 for frequencies).
Combinations of different types of tremor were
observed in 45 PD patients but 29 % of these patients
presented simply with a combination of rest and walking
tremors. (Fig. 2).
The classic walking tremor was observed in 80 % of
tDLB and 72.3 % of tPD patients but in none of ET patients.
Isolated arm rest tremor was observed in only 3.3 % of
DLB patients compared with 30.8 % of PD (v2 = 5.6;
p = 0.02). The tDLB patients did not present with isolated
postural or action tremor nor the combination of the two;
instead this tremor pattern was observed in 70.6 % of ET
patients. Tremor frequencies did not differentiate specific
tremor patterns although the head tremor had a significantly
lower frequency than rest and postural (Wilcoxon test,
Z = -3.6, Z = -3.1, respectively; p \ 0.001; Table 3).
Additional information is detailed in Online resource 2.
Regression analysis
In a stepwise regression analysis of the types of tremor
observed, the standing tremor proved to be the best pre-
dictor of membership in a disease group (B = -1.80;
Wald = 17.88; p \ 0.001; 95 % CI: 0.071, 0.38).
Table 1 Demographic and
clinical characteristics of groups
All values represent mean (SD,
when not otherwise stated).
Reported p values compare
between groups (DLB, PD and
ET) and within groups (baseline
and follow-up). The p values
have been calculated using
Oneway ANOVA with
Bonferroni corrections for
parametric variables and v2 for
categorical variables. Disease
duration indicates evidence of
cognitive decline in DLB
MMSE Mini Mental State
Examination, NP
neuropsychiatry inventory, FAB
frontal assessment battery, DRS-
2 Dementia Rating Scale-2,
CAF clinician assessment of
fluctuation, UPDRS-III Unified
Parkinson’s Disease Rating
Scale-subscale III, H/Y Hoehn/
Yahr staging, RBD REM sleep
behavior disorders, VH visual
hallucinations (also including
benign VH), NA not applicable,
NS not significant
a DLB different from PD and
ET
b ET different from PD and
DLB
c DLB different from PD
d PD different from ET
DLB (n = 67) PD (n = 111) ET (n = 34) p (between)
Age 72.15 (5.43) 66.52 (8.84) 67.79 (3.73) \0.005a
Gender (F/M) 35/31 51/60 16/18 NS
Disease duration 2.86 (0.95) 4.07 (3.1) 4.7 (1.91) \0.001a
UPDRS III
Baseline 26.98 (5.14) 24.47 (12.4) NA \0.001b
Followup 21.61 (5.28) 18.01 (11.44) NA
p (within) \0.001 \0.001
MMSE
Baseline 18.11 (3.27) 28.07 (1.5) 28.7 (1.5) \0.001a
Followup 12.95 (2.78) 26.82 (1.93) 27.91 (2.1)
p (within) \0.001 \0.001 NS
DRS2
Baseline 84.05 (12.82) 136.89 (7.08) 136.29 (2.6) \0.001a
Followup 61.61 (12.85) 132.04 (8.73) 135.78 (3.2)
p (within) \0.001 \0.001 NS
FAB
Baseline 12.41 (1.53) 17.09 (1.13) 17.54 (0.8) \0.001a
Followup 9.67 (1.36) 15.48 (1.3) 17.46 (1.1)
p (within) \0.001 \0.001 NS
CAF
Baseline 2.95 (1.4) 0.05 (0.42) 0 \0.001a
Followup 5.13 (1.31) 0.24 (1.03) 0
p (within) \0.001 \0.001 NA
NPI
Baseline 20.74 (1.6) 7.6 (2.84) 1.8 (1.7) \0.001b,d
Followup 28.74 (1.60) 8.61 (4.14) 1.9 (1.5)
p (within) \0.001 \0.001 NS
RBD (n/%)
Baseline 58 (86.6) 47 (42.3) 0 \0.001c
Followup 62 (92.5) 70 (63.1) 0
p (within) NS 0.033 NA
VH(n/%)
Baseline 49 (73.1) 0 0 NA
Followup 62 (92.5) 31 (27.9) 0
p (within) NS NA NA
J Neurol (2013) 260:1731–1742 1735
123
Specifically, the presence of standing tremor correctly
predicted 46.7 % of tDLB patients, and this percentage
increased to 53.5 % when standing and rest tremors entered
together in the model (for rest tremor, B = -0.47;
Wald = 4.74; p = 0.03; 95 % CI: 1.05, 2.47). Conversely,
the absence of standing tremor itself correctly predicted
96.9 % of tPD suggesting that standing tremor is rare in
PD. Roc analysis is reported in Online resource 3.
Effect of treatments
Acute treatments
L-Dopa significantly reduced tremor only in the tDLB
group (effect of drug, F = 8.56, p = 0.001; mean differ-
ence on TRGRS total score = 2.05, SE = 0.41, 95 % CI
0.84–3.24, p \ 0.001 Bonferroni corrected) while it was
ineffective in ET patients. It did improve tremor in a pro-
portion of tPD patients but this improvement was not sig-
nificant. An acute alcohol test significantly reduced tremor
in ET (effect of drug, F = 104.7, p \ 0.001; mean dif-
ference on TRGRS total score = 6.88, SE = 0.37, 95 %
CI 5.82–7.94, p \ 0.001 Bonferroni corrected) but was
ineffective in tDLB and tPD patients. Acute drug response
is depicted in Fig. 4a as a change in total TRGRS score, as
no differences in body distribution or the type of tremors
were noted following drug administrations.
Chronic treatment
Chronic dopaminergic treatments administration improved
all the types of tremors in tDLB (Wilcoxon test, Z values
range -2.9 and -4.2; p \ 0.005) and all but action tremor
in tPD (Wilcoxon test, Z values range -2.9 and -6.4;
p \ 0.005). The typical standing tremor observed in tDLB
improved from a mean TRGRS score of 2.25 to a mean
TRGRS score of 1.42 after chronic L-Dopa administration.
Total disappearance of tremor was observed in 12 tDLB
and 14 tPD patients.
Effect of chronic dopaminergic treatment on clustered
TRGRS items is illustrated in Fig. 4b. Mixed tremor with
overflow on a standing position disappeared in one PD
and in 12 out of 15 DLB patients. In all DLB patients
TRGRS scores for rest, postural or intentional tremor
components during L-Dopa treatment were reduced by
1–2 points on the TRGRS. Comparison of scores prior to
treatment and scores after six months of treatment dem-
onstrated that there was a 1–2 point reduction in the
TRGRS score, corresponding to reduction of 50–90 % for
rest, 60–90 % for postural and 60 % for the intentional
component. Head and chin tremor was reduced from a
score of 2–3 to 1 point in 4 DLB and 1 PD patient, and
was abolished (from score 2–0) in 1 DLB and two PD
patients, while these tremors were not modified in three
DLB and six PD patients.
During chronic L-Dopa treatment (mean daily dose
300 ± 45.5 mg), two patients (1 DLB, 1 PDD), whose
mixed tremor had been suppressed, showed a residual
small amplitude cortical mini-polymyoclonus in the fin-
gers, evident in outstretched horizontal position of the
arms, already described in association with Lewy body
pathology [3] which was undetectable before L-Dopa
administration, due to superimposition of postural tremor
components.
Table 2 Comparison between tremulous and non-tremulous patients within the DLB and PD groups
DLB (n = 67) PD (n = 111)
Tremor (30) Non-tremor (37) p Tremor (65) Non-tremor (46) p
Age 73.9 (5.17) 70.74 (5.3) 0.017 64.63 (9.82) 69.19 (6.44) 0.007
Disease duration 2.13 (0.86) 3.45 (0.5) \0.001 4.3 (3.31) 5.23 (2.86) NS
UPDRS III 25.5 (4.61) 28.18 (5.3) 0.032 23.52 (13.04) 25.82 (11.43) NS
MMSE 19.03 (2.56) 17.37 (3.61) 0.039 28.09 (1.72) 28.04 (1.31) NS
DRS2 87.96 (7.69) 80.89 (15.19) 0.024 136.16 (8.25) 137.91 (4.9) NS
FAB 12.36 (1.69) 12.45 (1.42) NS 17.03 (1.22) 17.17 (0.99) NS
CAF 3.2 (1.34) 2.75 (1.44) NS 0.09 (0.55) 0 NS
NPI 20.7 (1.55) 20.78 (1.66) NS 7.27 (3.14) 8.19 (2.26) NS
RBD (n) 28 30 NS 29 18 NS
VH (n) 24 25 NS 0 0 NA
All values represent mean (SD). p values have been calculated using Oneway ANOVA with Bonferroni corrections for parametric variables and
v2 for categorical variables
MMSE Mini Mental State Examination, NP neuropsychiatry inventory, FAB frontal assessment battery, DRS-2 Dementia Rating Scale-2, CAF
clinician assessment of fluctuation, UPDRS-III Unified Parkinson’s Disease Rating Scale-subscale III, H/Y Hoehn/Yahr staging, RBD REM sleep
behavior disorders, VH visual hallucinations (also including benign VH), NA not applicable, NS not significant
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Primidone
The eight DLB patients who received primidone (125
b.i.d. in 6, 250 mg b.i.d. in two) prior to referral to our
clinics presented with mixed tremors, including postural
action tremor with TRGRS score from 2 to 4 and variable
rest tremor (TRGRS score 1–3). Four of them presented
with standing tremor (TRGRS score 2,3). Primidone
withdrawal was not followed by tremor worsening
(Wilcoxon test, Z = -1.13; p = 0.25) with no differences
between tremor types. In the same patients chronic
L-Dopa therapy significantly reduced tremor scores (mean
Total TRGRS score difference = 14.1; Wilcoxon test,
Z value = -2.52, p = 0.012). Online Resource 4 shows
detailed results.
Discussion
Our cohort study showed that tremor occurred in 45 % of
DLB patients compared to 59 % of PD patients; thus it
confirmed that tremor is less frequent in DLB than PD but
challenged the assumption that tremor is rare in DLB.
Thus, our findings suggest that DLB, indeed, consists of
tremulous and non tremulous variants.
Furthermore our data shows that tremor in DLB patients
is in high prevalence a bilateral mixed tremor (postural,
action, standing with head tremor) and we demonstrated
that it shows responsiveness to L-Dopa treatment, but do
not respond to primidone or alcohol.
Strengths and limitations
The comprehensive nature of our assessments, including
the application of established diagnostic criteria [1] and of
SPECT and EEG assessments, of treatment protocols with
L-Dopa and alcohol, and of a wide spectrum of neuropsy-
chological test batteries and the two year follow-up
ensured a high degree of diagnostic certainty, within the
limit of clinical studies not supported by neuropathology
[3, 15, 29, 30]. In addition we could exclude that G20195
mutations in the LRRK2 gene, which associate with
tremors [27], were present in our cohort population.
A definite limitation is that our findings could not be
supported by neuropathological ascertainments, as no
ascertainment exists for ET.
Fig. 2 Graphic representation of prevalence of mixed tremor and
overlap of tremors in tDLB, tPD and ET. Notice the complexity of
mixed forms of tremor in tDLB as compared to tPD and ET. The
circle or ‘‘pie’’ graph on the upper half shows the general categories
of mixed (any combination) a or isolated forms of tremor, (rest)
b. The ring or exploded ‘‘doughnut’’ graph below each pie represents
separate subcategories of tremors in the same populations, as marked
by following symbols: m mixed, m1: sum of action postural rest arm,
action leg, ? walking tremor; m2: rest ? action ? walking tremor; m3:
rest ? action ? postural ? walking tremor; m4: rest ? action ?
walking ? standing tremor; m5: rest ? action ? walking ? postural
arm ? standing tremor; m6: rest ? walking tremor; m7: rest ?
walking ? postural tremor; m8: action ? postural tremor; m 1 f:
mixed ? face tremor; m 1 h: mixed ? head tremor; m 1 h/f:
mixed ? head ? face tremor; m 1 h/V: mixed ?head ? voice
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However, the majority of clinical studies, same as ours,
could not benefit from the support of neuropathology, but
yet were considered staminal studies [3, 14, 18].
A second possible limitation is the ascertainment bias of
patients referred to our centre, as we included all patients who
were referred to both our movement disorders and memory
clinics following procedures that underline our specific sci-
entific interest [29–32]. However the prevalence of tremor in
our cohort (45 %) was not different from prevalence rates
found in earlier studies [2, 3] conducted in memory clinics.
Characterisation of tremulous DLB (tDLB)
The tDLB patients had shorter disease duration and better
MMSE and DRS2 scores than non-tremulous ones and this
may be due to the fact that individuals with the obvious
symptom of tremor are referred earlier in their disease
course. The tDLB patients were also modestly older than
the nontremulous ones. We believe, however, that older
age does not indicate that senile tremor was overlapping
to DLB features, as the phenomenology and opposite
Fig. 3 Frequency analysis and
power spectra of tremor at rest
and during standing with wing
beating arm posture in a patient
affected by DLB. EXTENSOR
CARPI ULNARIS = ECU;
DELTOID = DEL; VASTUS
MEDIALIS = VM; TIBIALIS
ANTERIOR = TA Horizontal
scales represent frequencies in
Hz, (0–16 Hz) amplitude of
random noise frequencies are
0.2–0.6 lV2. A vertical red line
connects 5.6 Hz frequencies,
which is the specific tremor
frequency in this patient.
Horizontal arrows point to
minor frequency variations
(range 0.5–01 Hz) of the peak
amplitude. Notice overflow
during standing posture for the
same districts involved by the
rest tremor to other body
districts
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responses to L-Dopa and alcohol evidence that tremor in
tDLB was characterized by specific patterns.
In detail beyond rest tremor, the different tremor pat-
terns observed in tDLB were head and face [7, 8], postural
and action, re-emergent [9], walking and standing (also
called pseudo orthostatic) [5, 11, 12] tremors, which are
reported to occur in PD less frequently than rest tremor. In
addition, the standing/pseudo-orthostatic tremor [5, 11–13]
appeared to be particularly common in tDLB patients. The
standing posture revealed one further feature of this mixed
tremor: there was overflow from arms to other body dis-
tricts in a few seconds which might be considered a par-
ticularly severe example of the specific re-emergent
postural tremor described in PD [8], which is different from
postural tremor of ET, because in ET, posture elicits tremor
immediately, while the re-emergent tremor appears with a
delay when acquiring the posture (10 ± 4 in our cohort).
Due to the complex and variable expression of tremors
in DLB the regression analysis was weak at identifying a
single tremor type which was predictive of DLB although
the presence of standing tremor correctly predicted
(regression and ROC analysis) in about half of the tDLB
patients, with the same tremor being absent in ET and very
rare in PD.
Differential diagnosis was helped by identification of 4
tremor types: walking, re-emergent and standing tremor
were observed only in tDLB and tPD patients while the
voice tremor was only observed in ET patients.
Treatment of tremors in DLB
The second relevant finding of our cohort study was that in
DLB all types of tremors including head, mixed and
standing tremor showed a significant response to acute L-
Dopa challenge or chronic L-Dopa treatment and were not
modified by alcohol administration according to standard
tremor assessment protocols [35, 36], whereas ET was
reduced by alcohol. This not only has implications for
clinical practice but also for the aetiology of tremor in DLB
as it suggests that tremor in DLB, when present, arises
from dysfunction of the dopaminergic system and is a
unitary disorder specific to this condition rather than a
variant of ET or a senile tremor, or is due to concomitant
occurrence of both ET and DLB.
Further support to this conclusion was obtained in the
present study by the observation of the effect of primidone
withdrawal in eight patients who had received primidone
because of the initial diagnosis of ET but who presented
with all core and supportive consensus elements of DLB.
Primidone withdrawal had no effect on tremor in these
patients, also alcohol administration had no effect, while
their tremor was significantly reduced by L-Dopa (Online
Resource 4).
This minor part of our study, restricted to a small
number of patients, together with the other data, suggests a
further clinically relevant conclusion: the mixed pattern of
tremor (given the prominent action-postural components)
in DLB could be the source of possible misdiagnosis.
Some DLB patients were inappropriately, yet temporar-
ily, classified as having ET, but responses to treatment and
results of the comprehensive DLB-consensus-based assess-
ments, finally clarified the appropriate diagnosis (Fig. 1).
Our data thus would suggest that in some cases ET
patients are actually misdiagnosed tDLB patients.
Albeit prudent considerations are needed, in the absence
of neuropathology, this finding may provide additional
Fig. 4 Response to acute drug challenge and chronic treatment. The
scores are expressed as mean TRGRS scores. Bars represent the SE.
* p \ 0.01 a: acute treatment. Total TRGRS scores. Improvement
after L-Dopa administration was significant only in tDLB group
(p \ 0.001). Acute alcohol test improved tremor only in ET
(p \ 0.001). b Tremor in chronically treated patients clustered scores.
Rest tremor is the sum of head, face, rest arms and rest leg items;
postural tremor is the sum of forward arm and lateral arm items;
action is the sum of kinetic, action leg, spiral and water items, mixed
tremor defines any combination of rest, postural, action, standing and
walking tremors
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clarity to the on-going debate [38], opposing two factions,
suggesting [16–21] or denying [22–24] the possibility that
ET might evolve to PD or DLB, implicitly challenging the
assumption that the three do represent distinct clinical
entities rather than syndromes.
While recent studies [39, 40] might further help to
clarify this controversy, by adding new concepts to the
debate, our concluding remark would be focused to a
simple take home message: the appropriate examination
and investigation of patients with tremor should not be
simply addressed to motor aspects but should also consider
non-motor features and specifically the core and supportive
features of DLB [1–3] i.e., cognitive, visuo-spatial and
dysexecutive abnormalities, RBD, and EEG abnormalities,
before reaching definite conclusions.
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